AHB
BCLI

Abner Herrman & Brock’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Abner Herrman & Brock’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,700
Closed -$34K – 58
2024
Q3 		$34K Hold
9,700
– – ﹤0.01% 92
2024
Q2 		$49K Hold
9,700
– – 0.01% 88
2024
Q1 		$82K Hold
9,700
– – 0.01% 89
2023
Q4 		$40K Hold
9,700
– – 0.01% 94
2023
Q3 		$29K Sell
9,700
-8,967
-48% -$204K ﹤0.01% 89
2023
Q2 		$577K Hold
18,667
– – 0.08% 65
2023
Q1 		$924K Hold
18,667
– – 0.14% 61
2022
Q4 		$459K Hold
18,667
– – 0.07% 66
2022
Q3 		$1.24M Buy
18,667
+1,000
+6% +$50.2K 0.23% 48
2022
Q2 		$731K Hold
17,667
– – 0.13% 53
2022
Q1 		$890K Buy
17,667
+2,134
+14% +$105K 0.13% 55
2021
Q4 		$932K Buy
15,533
+1,866
+14% +$91.8K 0.12% 58
2021
Q3 		$676K Sell
13,667
-2,433
-15% -$128K 0.1% 61
2021
Q2 		$918K Hold
16,100
– – 0.13% 57
2021
Q1 		$925K Hold
16,100
– – 0.14% 61
2020
Q4 		$1.09M Buy
16,100
+67
+0.4% +$9.12K 0.17% 55
2020
Q3 		$4.07M Buy
16,033
+100
+0.6% +$20.5K 0.69% 42
2020
Q2 		$2.68M Buy
15,933
+12,196
+326% +$1.31M 0.48% 45
2020
Q1 		$260K Buy
+3,737
New +$292K 0.06% 72

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Abner Herrman & Brock's BCLI Position: Q4 2024 in Review

Abner Herrman & Brock sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 9,700 shares — an estimated $34K sold.

Abner Herrman & Brock first reported a position in BCLI in Q1 2020 and held it in 19 quarters. The position peaked at $4.07M in Q3 2020. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Abner Herrman & Brock reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Abner Herrman & Brock sold 9,700 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $34K.
  • Abner Herrman & Brock first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 19 quarters.
  • Abner Herrman & Brock's BRAINSTORM CELL THERAPUTC position peaked at $4.07M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Abner Herrman & Brock's 13F filing for Q4 2024, filed 24 Jan 2025.